Actively Recruiting
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2022-11-09
168
Participants Needed
13
Research Sites
417 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Intrahepatic cholangiocarcinoma (ICC) is one of the common malignant tumors. Lymph node metastasis is an important factor affecting the poor prognosis of intrahepatic cholangiocarcinoma. The eighth edition of the AJCC guidelines recommends at least 6 lymph nodes to be used for staging. The American Hepatobiliary and Pancreatic Association also recommends the removal of hilar lymph nodes as part of the radical surgery for intrahepatic cholangiocarcinoma. However, some scholars have found that patients with regional lymph nodes have similar survival rates. This contradictory result has prompted more scholars to conduct clinical research to explore the necessity and standardization of lymph node dissection in intrahepatic cholangiocarcinoma.
CONDITIONS
Official Title
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients between 18 and 80 years old
- Confirmed intrahepatic cholangiocarcinoma by preoperative imaging, intraoperative frozen, and postoperative pathology
- Tumor assessed as resectable by preoperative imaging
- No obvious lymph node metastasis on preoperative imaging or negative intraoperative lymph node biopsy
- Liver function classified as Child-Turcotte-Pugh grade A or B
- Residual liver volume greater than 30% and able to tolerate radical hepatectomy
- Patient is capable of understanding, voluntarily consents, and can complete follow-up
- Signed written informed consent before screening
You will not qualify if you...
- Significant heart, lung, brain, or kidney dysfunction affecting treatment
- History of other malignant tumors
- Liver function classified as Child-Turcotte-Pugh grade C
- Investigator judges patient unsuitable for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
The Johns Hopkins Hospital
Baltimore, Maryland, United States, 10017
Actively Recruiting
2
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
3
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
4
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China
Actively Recruiting
5
Hunan Provincial People's Hospital
Changsha, Hunan, China
Actively Recruiting
6
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China
Actively Recruiting
7
Renji Hospital Affiliated to Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China
Actively Recruiting
8
Xinhua Hospital Affiliated to Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China
Actively Recruiting
9
Zhong Shan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Actively Recruiting
10
The First Affiliated Hospital of Xi 'an Jiaotong University
Xi’an, Shanxi, China
Actively Recruiting
11
West China Hospital Sichuan University
Chengdu, Sichuan, China
Actively Recruiting
12
The Second Affiliated Hospital Zhejiang University School of Medicine
Hanzhou, Zhejiang, China, 310009
Actively Recruiting
13
Zhejiang cancer hospital
Hanzhou, Zhejiang, China
Actively Recruiting
Research Team
J
Jiang-Tao LI, PHD;MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here